Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$102.72 USD

102.72
7,656,647

-0.24 (-0.23%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $102.67 -0.05 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?

Nutrisystem's (NTRI) innovative products are expected to expand customer base that will eventually drive reactivation revenues in Q3.

    What to Expect From Thermo Fisher (TMO) in Q3 Earnings

    Thermo Fisher (TMO) gears up for another quarter of strong analytical instruments segmental growth. Improvement is likely to be seen in applied markets too.

      Phibro Animal Banks on Diverse Portfolio, Competition Rife

      Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.

        Henry Schein (HSIC) Inks Distribution Agreement with Terason

        Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.

          Will PBM Slowdown Hamper Express Scripts (ESRX) Q3 Earnings?

          Lackluster performance in PBM product network and services segment is likely to mar Express Scripts' (ESRX) revenues in the third quarter.

            Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings?

            We believe that the growing adoption of Intuitive Surgical's (ISRG) da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the quarter.

              Can CR Bard (BCR) Spring a Surprise This Earnings Season?

              We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon will result in improved performance for CR Bard (BCR) in Q3.

                The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

                The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

                  Can ResMed (RMD) Maintain Balanced Growth in Q1 Earnings?

                  ResMed (RMD) may ride high in Q1 on continued growth in its domestic as well as overseas business.

                    Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now

                    Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

                      Here's Why Investors Should Buy Integra LifeSciences Now

                      The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.

                        TransEnterix Senhance Surgical Robotic System Wins FDA Nod

                        TransEnterix (TRXC) works on expanding in robotic surgery consistently.

                          Abbott Banks on FDA Approvals and Buyouts, Competition Rife

                          The market is upbeat about Abbott's (ABT) latest initiatives.

                            MedTech Players Eyeing Emerging Market Growth Opportunities

                            The gloomy eco-political scenario in the United States and Europe points toward the fact that emerging geographies are playing a crucial role in the growth of the MedTech space globally.

                              DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                              DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.

                                Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders

                                Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.

                                  QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife

                                  The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.

                                    Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business

                                    Express Scripts (ESRX) is consistently trying to expand its core PBM business.

                                      Is a Beat in Store for Abbott (ABT) This Earnings Season?

                                      Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.

                                        Pacific Biosciences, Bluebee Team Up for De Novo Sequencing

                                        With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.

                                          QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite

                                          QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.

                                            Illumina (ILMN) Strong on Product Launches, Competition Rife

                                            Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.

                                              Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?

                                              The market is upbeat about Abbott's (ABT) recent FDA approvals and buyouts.

                                                Abbott to Gain from Alere's Takeover Due for Oct 3 Closure

                                                Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.

                                                  Abbott Gets FDA Nod for FreeStyle Libre, Boosts Diabetes Arm

                                                  Abbott's (ABT) diabetes care segment to strengthen with the FDA approval for FreeStyle Libre Flash glucose monitoring system.